Abilify Approval For Teens Is Bristol/Otsuka’s Latest Step In Franchise Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of the atypical antipsychotic for schizophrenia patients ages 13-17 comes more than two months after J&J’s Risperdal was cleared for adolescent schizophrenia.
You may also be interested in...
Bristol/Otsuka’s Abilify Approved To Treat Bipolar I Patients As Young As Age 10
Abilify now competes in the age 10-17 space with J&J’s Risperdal, approved in August.
Bristol/Otsuka’s Abilify Approved To Treat Bipolar I Patients As Young As Age 10
Abilify now competes in the age 10-17 space with J&J’s Risperdal, approved in August.
Bristol/Otsuka’s Abilify Gets FDA Nod For Use In Combination With Antidepressants
Aripiprazole becomes first drug approved as add-on treatment for major depressive disorder.